For global professionals tracking the convergence of advanced manufacturing and artificial intelligence, Shanghai is no longer just the world’s car capital—it is the laboratory where…
For global pharmaceutical and tech investors, the convergence of deep-pocketed AI giants and drug discovery marks a pivotal shift in how new therapies may be…
Tighter US visa rules for highly-skilled foreign workers are steering top talent away from Silicon Valley and toward Chinese labs and firms, accelerating a quiet…
For global professionals tracking the energy transition, CATL’s move signals that securing raw materials—not just battery chemistry—is now the defining strategic challenge. The company is…
While the United States maintains a lead in producing the most advanced AI chips, a quieter but consequential shift is underway: China is positioning itself…
For global pharmaceutical executives and investors, the coming wave of consolidation in China’s outsourced drug discovery sector signals an urgent window for strategic positioning in…
As autonomous machines approach the battlefield, the contest for industrial supremacy in robotics and AI is no longer a distant prospect but an urgent national…
The global AI race is less about who builds the fastest model and more about which nation can embed intelligence into the fabric of its…
For global investors and technology strategists, the emergence of a viable silicon photonic computing stack backed by an IPO-ready Chinese champion signals that the next…
For global pharmaceutical executives and investors tracking China’s ascent in innovative drug development, the scale of Chi-Med’s planned commercial buildout signals confidence not just in…
No products in the cart.
